Medicare AdvantagePrior AuthMedium impact
MA08.116e, Eptinezumab-jjmr (VYEPTI™)
Independence Blue Cross·Neurology, Pain Management, Pharmacy·Pharmacy
Effective date
Apr 6, 2026
We identified it
Jun 19, 2026
Summary
MA08.116e updates medical necessity criteria for Eptinezumab-jjmr (VYEPTI™), a monoclonal antibody used for migraine prevention. This policy change affects prior authorization requirements and coverage determinations for this pharmacy benefit on Medicare Advantage plans. Billing teams must verify current medical necessity documentation requirements before submitting claims.
Action Required
By April 6, 2026: Billing and prior authorization teams must review the full MA08.116e policy text to identify specific medical necessity criteria updates for Eptinezumab-jjmr (VYEPTI™). Update authorization request templates and internal guidelines to reflect new criteria. Inform providers of any documentation requirements changes. Before submitting claims for this drug, ensure all required medical necessity documentation is attached per the updated policy. Failure to meet updated criteria may result in claim denials. Contact the policy source URL for complete criteria details, as the specific requirements are not detailed in this notice.